State Street SPDR S&P Biotech ETF
663 hedge funds and large institutions have $9.05B invested in State Street SPDR S&P Biotech ETF in 2021 Q2 according to their latest regulatory filings, with 81 funds opening new positions, 250 increasing their positions, 178 reducing their positions, and 59 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 250 | Existing positions reduced: 178
37% more first-time investments, than exits
New positions opened: 81 | Existing positions closed: 59
3% more funds holding
Funds holding: 644 → 663 (+19)
15% less funds holding in top 10
Funds holding in top 10: 20 → 17 (-3)
20% less capital invested
Capital invested by funds: $11.4B → $9.05B (-$2.32B)
38.46% less ownership
Funds ownership: 156.53% → 118.08% (-38%)
41% less call options, than puts
Call options by funds: $1.39B | Put options by funds: $2.37B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$838M |
| 2 |
O
OrbiMed
New York
|
+$123M |
| 3 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
+$118M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$45.9M |
| 5 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
+$35.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.23B |
| 2 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$785M |
| 3 |
Goldman Sachs
New York
|
-$645M |
| 4 |
JP Morgan Chase
New York
|
-$295M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$138M |
XBI Hedge Fund Activity: Q2 2021 in Review
663 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q2 2021, worth a combined $9.05B — down 20% from $11.4B a quarter earlier.
Buyers outnumbered sellers: 81 funds opened new XBI positions and 59 closed out — a net gain of 22 holders — while 250 added to existing stakes and 178 trimmed.
The largest buyer was Toronto Dominion Bank, adding an estimated $838M. The largest seller was Morgan Stanley, cutting an estimated $1.23B.
- 663 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q2 2021, up from 644 in Q1 2021.
- Funds reported $9.05B of State Street SPDR S&P Biotech ETF stock for Q2 2021, down 20% quarter-over-quarter.
- 81 funds opened new State Street SPDR S&P Biotech ETF positions in Q2 2021 and 59 closed out, a net change of +22 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q2 2021 was Toronto Dominion Bank, an estimated $838M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q2 2021 was Morgan Stanley, an estimated $1.23B sold.
Based on aggregated 13F filings for Q2 2021.